3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
Cyclophosphamide
254
fludarabine phosphate
165
Cytarabine
160
Methotrexate
128
Busulfan
115
Filgrastim
111
fludarabine
102
Peripheral Blood Stem Cell Transplantation
96
Rituximab
94
Antilymphocyte Serum
83
Etoposide
81
Cyclosporine
75
Tacrolimus
74
Mycophenolic Acid
73
Whole-Body Irradiation
72
Radiotherapy
70
Melphalan
66
Vincristine
55
Dexamethasone
54
Granulocyte Colony-Stimulating Factor
50
Methylprednisolone
48
Azacitidine
44
Alemtuzumab
42
Imatinib Mesylate
41
Clofarabine
41
sargramostim
40
Idarubicin
36
Daunorubicin
36
Cord Blood Stem Cell Transplantation
36
Thiotepa
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia
×
Tablets
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled